{"id":"W1538245709","doi":"10.1002/cncr.27758","title":"Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma","year":2012,"lang":"en","type":"article","venue":"Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Genentech; Abbott Laboratories","keywords":"Medicine; Internal medicine; Gastroenterology; Clinical endpoint; Adverse effect; Progression-free survival; Hepatocellular carcinoma; Liver function; Phases of clinical research; Progressive disease; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002352118,0.0002153501,0.0005529641,0.0001613181,0.00003144434,0.000008323855,0.00007958478,0.00007079815,0.0009643068],"category_scores_gemma":[0.00005112407,0.0001409059,0.00009949858,0.0004198634,0.00006136925,0.0001612717,0.00002490433,0.0001404699,0.00001876561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001468032,"about_ca_system_score_gemma":0.0002829671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004108624,"about_ca_topic_score_gemma":0.00003730629,"domain_scores_codex":[0.9984895,0.00007996007,0.000377684,0.0002275691,0.0003865226,0.0004387922],"domain_scores_gemma":[0.9991356,0.00006839317,0.0001383515,0.0003078372,0.0001229099,0.0002268672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05328988,0.003556135,0.9386058,0.0001745221,0.000153046,0.00005468051,0.0004243272,3.279507e-7,0.0001534532,0.00001551202,0.000174864,0.003397398],"study_design_scores_gemma":[0.661716,0.01818236,0.2639057,0.0004695371,0.001809977,0.000006849057,0.0001866281,0.001058715,0.04391208,0.00001492174,0.008108966,0.000628258],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955963,0.001722288,0.00002054437,0.00006356853,0.0002275196,0.001890408,0.00005504068,0.00002033122,0.0004039241],"genre_scores_gemma":[0.9982074,0.00004714693,0.0004369041,0.0000790113,0.0001784869,0.0003450318,0.0001002099,0.00004173722,0.0005640199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6747001,"threshold_uncertainty_score":0.9999489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09270249027125183,"score_gpt":0.3175934619452295,"score_spread":0.2248909716739776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}